BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 18474620)

  • 1. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor.
    Guigon CJ; Zhao L; Lu C; Willingham MC; Cheng SY
    Mol Cell Biol; 2008 Jul; 28(14):4598-608. PubMed ID: 18474620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression.
    Ying H; Furuya F; Zhao L; Araki O; West BL; Hanover JA; Willingham MC; Cheng SY
    J Clin Invest; 2006 Nov; 116(11):2972-84. PubMed ID: 17039256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis.
    Kato Y; Ying H; Willingham MC; Cheng SY
    Endocrinology; 2004 Oct; 145(10):4430-8. PubMed ID: 15231697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor suppressor action of liganded thyroid hormone receptor beta by direct repression of beta-catenin gene expression.
    Guigon CJ; Kim DW; Zhu X; Zhao L; Cheng SY
    Endocrinology; 2010 Nov; 151(11):5528-36. PubMed ID: 20844001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel oncogenic actions of TRbeta mutants in tumorigenesis.
    Guigon CJ; Cheng SY
    IUBMB Life; 2009 May; 61(5):528-36. PubMed ID: 19391168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance.
    Miller LD; McPhie P; Suzuki H; Kato Y; Liu ET; Cheng SY
    Genome Biol; 2004; 5(5):R31. PubMed ID: 15128445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of thyroid hormone receptor-β in mice predisposes to the development of mammary tumors.
    Guigon CJ; Kim DW; Willingham MC; Cheng SY
    Oncogene; 2011 Jul; 30(30):3381-90. PubMed ID: 21399657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
    Furuya F; Lu C; Willingham MC; Cheng SY
    Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
    Furuya F; Hanover JA; Cheng SY
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1780-5. PubMed ID: 16446424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.
    Lu C; Zhao L; Ying H; Willingham MC; Cheng SY
    Endocrinology; 2010 Apr; 151(4):1929-39. PubMed ID: 20133453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis.
    Furumoto H; Ying H; Chandramouli GV; Zhao L; Walker RL; Meltzer PS; Willingham MC; Cheng SY
    Mol Cell Biol; 2005 Jan; 25(1):124-35. PubMed ID: 15601836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis.
    Guigon CJ; Cheng SY
    Mol Cell Endocrinol; 2009 Sep; 308(1-2):63-9. PubMed ID: 19549593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of tyrosine phosphorylation at Y406 abrogates the tumor suppressor functions of the thyroid hormone receptor β.
    Park JW; Zhao L; Willingham MC; Cheng SY
    Mol Carcinog; 2017 Feb; 56(2):489-498. PubMed ID: 27254276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked potentiation of the dominant negative action of a mutant thyroid hormone receptor beta in mice by the ablation of one wild-type beta allele.
    Suzuki H; Zhang XY; Forrest D; Willingham MC; Cheng SY
    Mol Endocrinol; 2003 May; 17(5):895-907. PubMed ID: 12576488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
    Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
    Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
    Guigon CJ; Zhao L; Willingham MC; Cheng SY
    Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear receptor corepressor is a novel regulator of phosphatidylinositol 3-kinase signaling.
    Furuya F; Guigon CJ; Zhao L; Lu C; Hanover JA; Cheng SY
    Mol Cell Biol; 2007 Sep; 27(17):6116-26. PubMed ID: 17606624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer.
    Kim CS; Furuya F; Ying H; Kato Y; Hanover JA; Cheng SY
    Endocrinology; 2007 Mar; 148(3):1306-12. PubMed ID: 17170101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of thyroid hormone receptor isoforms dictates the dominant negative activity of mutant Beta receptor.
    Zhang XY; Kaneshige M; Kamiya Y; Kaneshige K; McPhie P; Cheng SY
    Mol Endocrinol; 2002 Sep; 16(9):2077-92. PubMed ID: 12198244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel functions of thyroid hormone receptor mutants: beyond nucleus-initiated transcription.
    Furuya F; Ying H; Zhao L; Cheng SY
    Steroids; 2007 Feb; 72(2):171-9. PubMed ID: 17169389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.